Metastatic Cancer Drug Market
Pharmaceuticals

Metastatic Cancer Drug Market Medical Requirement : Global Analysis

Metastatic cancer is stage 4 or advanced-stage cancer that occurs when primary cancer has spread to other parts of the body and metastatic cancer drugs are used for the treatment of such an aggressive form of cancer. These drugs can be used via different therapies such as immunotherapy, targeted therapy, and chemotherapy.

Hoffmann-La Roche Ltd and Bristol-Myers Squibb Company – Notable Market Players in Metastatic Cancer Drug Market

The metastatic cancer drug market majorly comprises top players involving AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., Novartis AG, ASTRAZENECA PLC., Eli Lilly and Company, MERCK KGaA, and Pfizer Inc. (Arena Pharmaceutical GmbH).

The companies listed above are implementing various strategies that have resulted in the growth of the company and in turn, have brought about various changes in the worldwide market. Additionally, the companies have adopted several inorganic and organic strategies for accelerating their growth and improving their market position.

Below is the list of the growth strategies done by the players operating in the metastatic cancer drug market:

Year News
January–2022 AbbVie announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.
January–2022 Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based chemotherapy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression.
March–2022 Novartis announced that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic).
October–2021 Roche announced U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company’s commitment to guide clinical decision making through innovative, high-quality assays that improve patient access to personalized healthcare.
May–2021 Amgen announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
January–2021 AbbVie and Genmab have entered a broad collaboration agreement to jointly develop and commercialize three of Genmab’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for antibody therapeutics for cancer.